Patient adherence and persistence with oral anticancer treatment
By Kathryn J. Ruddy, E. Mayer, A. Partridge. Ca, 2009
596 citations recorded by the source corpus.
Given the recent significant increase in the use of oral therapies in cancer management, an understanding of patients' adherence to and persistence with oral therapy is crucial. Nonadherence and early cessation may be substantial barriers to the delivery of valuable therapies, and may impair health. Potential obstacles to adherence and persistence include personal characteristics, treatment features, and system factors. Techniques for measuring adherence and persistence include self‐report, pill counts, microelectronic monitoring systems (MEMS), prescription database analysis, and the assessment of serum or urine drug levels. This review article describes available data regarding adherence and persistence among patients with cancer, as well as studies of interventions to improve adherence. All reports of studies of adherence with oral cancer therapy that the authors could find on PubMed or in the reference sections of these PubMed‐located articles were included. Adherence and persistence rates ranged from 16% to 100% with different therapies and different methods of measurement. Studies that included educational, behavioral, and multidimensional interventions to improve adherence were also described. CA Cancer J Clin 2009;59:56–66. © 2009 American Cancer Society.
Subfields: Family Practice, Pediatrics, Perinatology and Child Health, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/feb60c943e7d5a9a96b492c673b04f64027bc1aa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Apperley
- J. Goldman
- D. Marin
- F. Mahon
- A. Bazeos
- L. Eliasson
- D. Milojkovic
- M. Bua
Citations in the corpus
- Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010, methodology): “The extent to which patients with cancer comply with prescribed oral anticancer therapy ranges between 16% and 100%, depending on the specific therapy and method used to measure adherence.(10) The methods used to monitor drug adherence include self reporting, frequency of repeat prescriptions, pill ”
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline (2016, unknown): “Reported adherence to a 5-year course of therapy ranges from 50% to 92% of breast cancer patients.(43) Primary care clinicians should assess and encourage adherence to adjuvant endocrine therapy at each visit.”
- Adherence to Adjuvant Hormonal Therapy among Breast Cancer Survivors in Clinical Practice: A Systematic Review (2012, unknown): “Persistence was defined as the duration from initiation to discontinuation of therapy [21].”
- Determinants of patient adherence: a review of systematic reviews (2013, background): “…Munro et al., 2007; Reisner et al., 2009) More visits to a nonmedical therapist (Lanouette et al., 2009) Seeing a greater number of physicians (Ruddy et al., 2009) Clinic attendance (Jindal et al., 2003) Abbreviations: GP, general practitioner; TB, tuberculosis; P , determinant of…”